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Abstract
Objectives The main objective of present review is to explore and evaluate the effectiveness of recently developed methods to
improve the bioavailability of orally administered biopharmaceutical drugs.
Methods A systematic search of sciencedirect, tandfonline and Google Scholar databases based on various sets of keywords was
performed. All results were evaluated based on their abstracts, and irrelevant studies were neglected during further evaluation.
Results At present, biopharmaceuticals are used as injectable therapies as they are not absorbed adequately from the different
routes of drug administration, particularly the oral one. Their insufficient absorption is attributed to their high molecular weight,
degradation by proteolytic enzymes, high hydrophilicity and rigidity of the absorptive tissues. From industrial aspect incorpo-
ration of enzyme inhibitors (EIs) and permeation enhancers (PEs) and mucoadhesive polymers into conventional dosage forms
may be the easiest way of formulation of orally administered macromolecular drugs, but the effectiveness of protection and
absorption enhancement here is the most questionable. Conjugation may be problematic from regulatory aspect. Encapsulation
into lipid-based vesicles sufficiently protects the incorporated macromolecule and improves intestinal uptake but have consid-
erable stability issues. In contrast, polymeric nanocarriers may provide good stability but provides lower internalization efficacy
in comparison with the lipid-based carriers.
Conclusion It can be concluded that the combination of the advantages of mucoadhesive polymeric and lid-based carriers in
hybrid lipid/polymer nanoparticles may result in improved absorption and might represent a potential means for the oral
administration of therapeutic proteins in the near future.
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Introduction
Various diseases like diabetes, malignant tumors and some
types of infections have been managed by peptides and pro-
teins. In addition, peptides and peptidomimetics can serve as
immunomodulating agents [1]. They produce their response
either by antigenic properties or by stimulating the immune
system as an agonist. Some intensively investigated peptides,
such as cyclosporine, tuftsin, muramyl dipeptide (MDP) and
thymic peptide analogues have already been used as therapeu-
tic peptides [2]. Host defense peptides (HDPs) were accepted
on a large scale as immune system stimulators and modula-
tors, their effects include wound healing and the induction of
both intra- and extracellular bactericidal effect through phago-
cytosis [3]. Consequently, biopharmaceuticals, including hor-
mones, enzymes and immunomodulators, play an important
role through the controlling of various functions, therefore
they are useful in clinical practice to treat or prevent human
disorders pathophysiological processes [4]. These days vari-
ous macromolecules are intensively examined and more than
thirty have been accepted by the Food and Drug
Administration (FDA) for commercialization [5].
The design, formulation and peroral administration of ther-
apeutically active biomolecules have represented a difficulty
as well as a target for several years, and until now only a few
biopharmaceuticals (insulin derivatives, interferon alpha,
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calcitonin, growth hormone, etc.) are known to be in clinical
development [6, 7], and even less macromolecule is commer-
cialized currently for oral administration (Table 1).
As a class, biopharmaceutical drugs, such as proteins and
peptides, have the advantages of higher potency and specific-
ity compared to small molecular drugs. These advantages are
related to their rigid and complex structure, which at the same
time represents the greatest obstacle in designing and formu-
lating an oral delivery system of these macromolecules [8].
Accordingly, in the past significant interest was focused on the
delivery of oral macromolecules in the hope of controlling
different diseases and achieving better patient compliance by
employing advanced pharmaceutical biotechnology for pro-
duction and development [9]. Recently, the formulation of
polymers with mucoadhesive properties as intestinal patches
containing safe surfactant, as an oral insulin delivery system,
has been one of the most studied techniques [10].
Biocompatible and biodegradable polymeric nanocarriers
and lipid based nanoparticles have also come forth as promis-
ing oral delivery platforms for these biopharmaceuticals, as
these systems give protection against proteases as well as con-
trol the release of proteins [11, 12]. The increasing importance
of proteins/peptides can be explained as a result of three main
developments: evolution in the analytical methods, which has
promoted the discovery of a huge number of peptides and
hormones applicable as biopharmaceuticals; good knowledge
about the role of these molecules in the regulation of human
pathophysiology; and the development of biotechnology and
genetic engineering, which enables the production of biomol-
ecules in a bulk quantities [13].
Barriers to oral absorption
Any orally administered drug will face many barriers while
passing along the gastrointestinal tract (GIT) before reaching
the targeted absorptive capillaries at the absorption site of the
sub-epithelial tissue. Themost frequently encountered barriers
are stomach acidity and the intestinal milieu, the tight junc-
tions (TJs), which prevent the paracellular way, the external
cells of the GIT and finally the subepithelial tissues [14]. The
epithelium layer of the intestinal tract is a group of consoli-
dated cells which act as a cover for the GIT and as mucosal
immunological defense against the invading pathogens and
harmful chemicals. The most common absorptive areas
throughout the intestine are the microvilli covered apical sur-
faces of enterocytes, which are negatively charged. The dis-
tance between microvilli is around 25 nm, thus they prevent
the passage of larger molecules [15]. Therefore, these cells act
as a physical-, whereas the degrading enzymes represent a
biochemical barrier. Therefore the understanding of the these
barrier mechanisms and finding the way to overcome the lim-
itations of macromolecule transportation are essential to de-
velop effective oral protein/peptide delivery systems [16, 17].
The crossing of the cell barrier is possible via various ways;
passively through diffusion, crossing the hydrophobic TJs or
transepithelial cells, transcellularly via facilitated transport
and by carrier-mediated transport (Fig. 1) [18]. Moreover,
the absorption of both some biomolecules and some drugs
may vary along the various parts of the GIT due to variation
in the pH values, surface areas, activity of proteases and per-
meability of the absorptive site. Therefore, the determination
of the proper region of the GIT for the chosen peptide/protein
will be the primary step in the design and development of an
oral dosage form with improved bioavailability [19].
Intestinal digestive environment
The greatest difficulty encountered in the case of orally ad-
ministered bioactive macromolecules is the lumen of the small
intestine, where there is high concentration of proteolytic en-
zymes secreted by the pancreas and by mucosal cells. Another
main enzymatic obstacle is the border of the epithelial cells,
which contains around fifteen degrading enzymes with high
selectivity for the breakdown of the macromolecular biomol-
ecules [20]. In addition, the colon contains various enzymes
produced by the local microflora, which should also be taken
into account [21]. Generally, the degradation of administered
biomolecules depends on numerous mechanisms adopted by
these enzymes, and the overall result is that the byproducts of
macromolecule degradation, such as short peptide chains and
amino acids, have no ability to produce the required effect
[22].
Tight junction (TJ)
As mentioned above, drugs may penetrate across the mem-
branes through the following pathways: paracellular pathway,
transcellular pathway and through transport via microfold
cells. Recently, some researchers have investigated the appli-
cability of the absorption of drug entities from the small intes-
tines via receptor-mediated, clathrin-mediated and even
caveolae-mediated endocytosis. Most drugs are transported
transcellularly, but for hydrophilic molecules (like proteins
and peptides) paracellular absorption is the main pathway.
However, this gate is tightly closed by tight junctions (TJs)
[23, 24]. TJ proteins are associated with higher paracellular
permeability, which is highly explicit throughout the small
Table 1 Macromolecules commercialized for oral administration
Trade name Drug Company
Leftose Lysozyme Wellchem
Linzess Linaclotide Allergan
Trulance Plecanatide Synergy Pharmaceuticals
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intestines [25]. TJs contain four types of unique transmem-
brane proteins: occludin, claudins, junctional adhesion mole-
cules (JAMs) and tricellulin [26]. TJs are not static protein
structures, they serve as penetration regulators of the mole-
cules across the intestinal epithelium. Some penetration en-
hancers have the ability to loosen the TJs and thus facilitate
the paracellular absorption of drug molecules [27].
Mucous barrier
The mucosa is covered by the mixture of mucins, ions and
proteins; therefore, it is a rigid layer which acts as a coat to the
intestinal lumen and is bound to the surface by a glycoprotein
structure (about 500-nm thick). The primary role of the mu-
cosal layer is the regulation of pH at the lumen surface and
thus results in the formation of an acidic microenvironment
[28]. The mucosal layer has different thickness and turnover
values regarding the anatomical position, pathophysiological
status and interaction with the external environment [29].
Generally, the mucous layer acts as a physical barrier as a
result of its negative charges and lipophilic nature, whereas
the general hydrophilicity of mucus also acts as an interactive
barrier, which retards the movement of the molecules within
and through the mucus. The dynamic behavior of the mucosal
layer is due to its continuous secretion and sloughing from the
surface of the mucosal membrane, therefore mucus represents
a rigid gel barrier to drug delivery [30].
Formulation aids and techniques
for improving bioavailability
Due to limiting factors such as large molecular weight, hydro-
philic nature, inactivation due to stomach secretions and in-
testinal proteases, first pass effect, and tendency to aggrega-
tion, the bioavailability of orally administered proteins/
peptides is usually recorded less than 1% [31]. Numerous
approaches have been taken by researchers to improve the oral
delivery of therapeutic proteins, like insulin. The most studied
strategies include the use of permeation improvers, protease
inhibitors, mucoadhesive polymers, polymeric nanoparticles,
liposomal encapsulation, modification of the structure and mi-
crosphere encapsulation [7, 24].
Permeation enhancers approach (PEs)
The use of permeation enhancers represents the most common
approach of protein delivery, their use can modulate the charac-
teristics of the absorptive epithelium and may facilitate both
transcellular or paracellular absorption. Therefore, it is an appli-
cable strategy to enhance the bioavailability of administeredmac-
romolecules [32]. These agents were first investigated twenty
years ago to enhance the absorption of pharmacologically active
molecules with poor bioavailability due to their low permeability
as well as in an attempt to develop non-injectable systems for
insulin delivery [33]. The enhancing effect through the
Fig. 1 General pathways of
absorption across the small
intestines
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paracellular pathway is due to the opening of TJs, whereas the
transcellular pathway ensues from the increased permeability of
the plasma membrane. Both pathways may be possible for one
enhancer, but the number of enhancers that increase transcellular
membrane permeability is 10 times higher than the number of
those increasing paracellular absorption [34]. Calcium chelators
act by stirring the cells through calcium depletion, which results
in loosening the attachments of the TJs. In contrast, surfactants
work through the disruption of the barrier function of the epithe-
lium [35]. The less damaging paracellular pathway by a transient
opening of TJs seems to be more rational and safer when com-
pared to the disruption of the cell membrane structure.
Nevertheless, the successful improvement of oral bioavailability
in vivo necessitates the concurrent delivery of the drug and effi-
cient concentrations of the absorption promoter to the intended
absorption site [36]. It is also notable that the effectiveness of
absorption enhancers is not the same along the GI tract due to the
variations of numerous parameters, such as membrane thickness,
morphology of the cells, proteolytic activity, lipid composition
and fundamental protein interactions [37]. Moreover, despite the
effective promotion of the oral absorption of poorly absorbable
molecules, the use of PEs should be evaluated carefully as they
can cause non-specific absorption and they must be avoided in
the case of patients suffering from irritable bowel disease, celiac
disease and inflammatory bowel disease [38]. Therefore, PEs
offer the greatest potential when incorporated in localized deliv-
ery systems, like hydrogels and intestinal patches, to avoid non-
specific absorption [39].
The general classes of PEs are demonstrated below in
Table 2.
Besides the promotion of the transport of small drug mol-
ecules, sodium salicylate and EDTA have also demonstrated
an improved oral bioavailability of insulin in dogs and rabbits
[50]. They increase the paracellular transport of drug entities
through affecting the permeability of TJs by chelating the
membrane-bound calcium ions [51].Medium chain fatty acids
(as shown in Table 1) and gel-forming polymer media for
example, octreotide may be also utilized to improve the effi-
ciency of orally administered macromolecules [33]. Chitosan
is a positively charged polymer commonly considered as an
effective and harmless penetration enhancer for therapeutic
macromolecules along the intestinal lumen via a reversible
integrity modulation of epithelial TJs in a concentration de-
pendent manner [52–54]. Phenyl piperazine at a concentration
of 0.1%w/w has also been considered as a safe and effective
transepithelial permeation enhancer amongst fifty-one studied
promoters from eleven discrete chemical categories [39].
Sodium dodecyl sulfate (SDS) has also been reported as an
effective, potent and safe absorption enhancer in oral formu-
lations, as neither the change the epithelial surface, nor toxic
luminal absorption has been reported [55]. Bile salts may
serve as effective aids in drug formulation since they may
improve absorption through both transcellular and intercellu-
lar paths. An investigation has shown the enhancement of
heparin absorption by either the chemical conjugation of hep-
arin or physical mixing with bile acids [55–57].
Enzyme inhibitors (EIs) approach
One of the key issues to achieve appropriate oral activity is to
protect the therapeutic peptides against luminal breakdown
caused by the presence of various proteases. The inhibition
of these proteolytic enzymes is achieved mainly by two mech-
anisms: local modulation of the pH away from the optimum
ranges of peptidases or binding to target enzymes and limiting
their activity [58]. In recent studies the use of numerous tryp-
sin and α-chymotrypsin inhibitors have been investigated,
such as soybean trypsin inhibitor, camostat mesylate, pancre-
atic inhibitor, amastatin, bestatin, aprotinin, boroleucine,
bestatin, and aminopeptidase inhibitors, such as puromycin,
to control the effect of these enzymes [16, 59]. The coadmin-
istration of oral insulin and EIs resulted in an improved hypo-
glycemic effect, which may be explained either by protecting
insulin from the degradation activity of proteases or enhancing
the absorption of insulin, or both at the same time [60].
Similarly, the concurrent administration of insulin microcrys-
tals with protease inhibitor resulted in improved bioavailabil-
ity also in the case of pulmonary delivery, and the absorption
Table 2 Classification of permeation enhancers [33, 40–49]
Class Example Mechanism and pathway
Surfactants polysorbates, poloxamer 407, Tween 80, labrasol,
sodium dodecyl sulphate, lauryl methyl glucamide
inhibiting the effect of P-glycoprotein andmodulating TJs,
transcellular and paracellular pathways
Chitosan derivatives Di- and tri-methyl chitosan, carboxymethyl chitosan Strong mucoadhesion, opening tight junctions, maily
paracellular pathway
Multicarboxylic acids Citric acid, ethylenediaminetetraacetic acid (EDTA) Chelating the calcium ions at the absorptive tissues
and loosening the TJs, mainly paracellular pathway
Bile acid salts Sodium cholate, glycocholate, taurocholate and
deoxycholate
Enhancing lymphatic uptake or modulating TJs, both
transcellular and paracellular pathways
Fatty acids and fatty alcohols Stearic acid, octanoic acid, palmityl alcohol
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enhancement was the highest with soybean trypsin inhibitor
among all the tested inhibitors [61]. Duck and chicken
ovomucoids (DkOVM and CkOVM) have been reported as
a unique class of protease inhibitors. Dissolution stability in-
vestigations showed that the percentage of insulin remaining
for absorption increased dramatically against the action of
proteases (trypsin and chymotrypsin) when administered with
CkOVM and DkOVM [62].
As it was mentioned above, another technique to inhibit
enzyme activity is to modify the pH at the targeted absorption
site as the activity of proteases is extremely sensitive to pH
change; intestinal proteases are active at a relatively elevated
pH, thus lowering the pH at this site may decrease the activity
of the enzymes present [63]. A pH modulator like citric acid
(CA) can be utilized to suppress lumen peptidases, and it has
been reported to be a helpful excipient for the oral delivery of
some peptides, as the proteolytic action is particularly elevated
in the upper part of the intestines [58]. Nevertheless, safety
issues should be taken into consideration for formulations that
contain any kind of protease inhibitors as these agents may
interact with dietary proteins or rupture the integrity of the
mucosal surfaceand cause upregulated enzyme secretion after
long-term treatment [64, 65]. Moreover, the use of enzyme
inhibitors may increase the amount of the intact drug at the
absorption site but will not help passing through biological
membranes. Therefore, the combination of the various ap-
proaches may be essential to have an appropriate therapeutic
effect. In a recent study, enteric-coated capsules have been
developed for oral insulin delivery, consisting of a greasy
mixture of omega-3 fatty acids, containing insulin, EI such
as aprotinin and chelating agent or bile acid salt as PE acid.
This formulation has passed Phase II-a of clinical trials and is
progressing into Phase II-b [66].
Bioadhesive polymer approach
Bioadhesion is a circumstance resulting from the attractive
forces generated between a polymer and the surface of biolog-
ical substrates, which enables the polymer to tightly stick to
the biological substrate for various periods of time, depending
on the nature of the forces participating [67]. As regards the
phenomenon of mucoadhesion, two phases can be distin-
guished: the adhesion phase between the polymer and the
mucosa, which enables the polymer to diffuse and dilate,
and the integration phase as a result of the development of
different adhesion forces (Fig. 2) [67, 68].
To date, six hypotheses have been proposed to express the
phenomena behind the two stages of mucoadhesion, which
are:
(a) The electronic theory is based on the transfer of electrons
amongst the polymer backbone and the substrate, leading
to the development of binding forces.
(b) The wetting theory proposes the higher affinity of the
surrounding liquid to substrate surface to the surrounding
liquid medium resulting in case of lower angle of
contact.
(c) The cohesive theory describes that bioadhesion phenom-
ena are basically attributed to the interactions arising be-
tween similar molecules.
(d) The adsorption theory expects the existence of molecular
attraction based on van der Waals or H-bonding between
the surfaces of the biological substrate and the polymer.
(e) The diffusion hypothesis supposes the formation of a
networked structure as a result of the polymer backbone
spreading on the mucosal surface along the adherent
interface.
(f) The mechanical hypothesis describes the adhesion devel-
oping between the substrate and the polymer as a result of
the interlinking of the polymer’s structure with the micro-
holes present on the biological surface [69].
The effectiveness of various drugs may be improved by
applying mucoadhesive delivery systems, which stay in direct
contact with the targeted mucosal surface, hence they release
the incorporated macromolecule directly to the absorptive tis-
sues, thus enhancing the delivery efficiency, and they can be
used either for local or systemic effects. Therefore,
mucoadhesive polymeric systems are attractive carriers for
protein delivery as their properties may be tuned as a result
of various changes in their network structure or swelling be-
havior as a response to various surrounding triggers, e.g. the
change of pH, electric field, temperature, light or ionic
strength [59]. In addition, they may isolate protein/peptide
from the degradation effect of the low gastric pH as well as
of proteolytic enzymes [70–72]. Moreover, they control the
release of incorporated molecules from the delivery system
and provide the concurrent release of the drug and the enzyme
inhibitor. Furthermore, they also localize the effect of enzyme
inhibitors as well as make the drug closer to the absorption site
for a sufficient time [73]. This effectiveness was confirmed in
recent studies, where mucoadhesive devices containing a mix-
ture of polymers with mucoadhesive character were devel-
oped. These enteric coated devices were entirely coated with
water impermeable backing layer except on one side, where
the device will adhere to the intestinal mucosal membrane,
making the release of incorporated macromolecules possible
in a unidirectional pattern. These devices provide protection
from luminal proteases; therefore, they prevent the loaded
drug from enzymatic degradation. Moreover, the investiga-
tions showed that the developed devices are safe and can
tolerate the shear stress of peristalsis due to strong
mucoadhesion, and were reported as an efficient alternative
to insulin injection in controlling diabetes [74, 75].
There are numerous available and commonly used
mucoadhesive polymers including chitosan, carbopol,
DARU J Pharm Sci (2020) 28:403–416 407
cellulose derivatives and alginate. Nevertheless, the selection
of the polymer type and its molecular mass should be done
very carefully before utilizing it in the formulation, as the
release of the peptide may be retarded because of steric hin-
drance if polymers with a higher molecular weight are used
[76]. Most of the polymers which exhibit the strongest inter-
action with mucins are hydrophilic and positively charged
under the pH conditions of the GIT. Chitosan (poly [ß-(1–4)-
2-amino-2-deoxy-D-glucopyranose]), a positively charged
polymer derived by the partial deacetylation of chitin [77],
was described to form a strong matrix with mucus glycopro-
tein, enabling it to release insulin and significantly controlling
the plasma glucose levels in normal rats for 24 h [78]. In
addition, chitosan can sustain drug release, extend the duration
of drug treatment time and concurrently enhance the
mucoadhesive force of drug particles to the mucosal mem-
brane at the absorption site [79].
Chitosan and its derivatives have been utilized by many
researchers for protein/peptide delivery particularly because,
besides their mucoadhesive properties, they are recognized as
effective and safe absorption enhancers, which considerably
improves their capacity for the delivery of hydrophilic mac-
romolecules through the (nasal and peroral) mucosa [80]. The
mechanism of permeation enhancement is attributed to the
free positive charges, enabling strong adhesion with the
absorptive substrate and leading to the modulation of the TJ
proteins [81]. As it was discussed above, the interaction be-
tween the mucosal membrane (mucin) and polymers is mostly
based on non-covalent bonds, but some polymers are also able
to form covalent bonds [82]. This novel class of
mucoadhesive polymers, often called multifunctional poly-
mers, have recently replaced conventional polymers on the
market thanks to their distinctive attributes, such as consider-
ably improved mucoadhesive characteristics and similarly im-
proved permeation enhancing effects [83]. These novel poly-
mers (like poly (acrylic acid)–homocysteine, chitosan–
iminothiolane, chitosan–thioglycolic acid, poly (acrylic ac-
id)–cysteine, chitosan–thioethylamidine, alginate–cysteine,
poly (methacrylic acid)–cysteine and sodium carboxymethyl-
cellulose–cysteine) have been produced by thiomerization.
This improves their water uptake, which – along with intra-
and interchain disulfide linkages – improves viscosity,
strengthens cohesiveness and mucoadhesion, which are in
turn responsible for the prolonged residence of the polymeric
system at mucosal surfaces [84, 85]. The newly developed
preactivated polysulfonate thiomers also showed a distinct
improvement in the paracellular transport of both low and
high molecular weight hydrophilic penetration markers along
the monolayer cells of Caco-2 of newly enucleated rat gut;
therefore thiolated polymers are recommended as potential
Fig. 2 The attachment and consolidation stages of a positively charged mucoadhesive polymer
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carriers, particularly for orally administered macromolecules
[86].
Prodrug approach
Prodrugs are inactive forms of therapeutic molecules pro-
duced via the chemical modification of the original molecule,
which turns into the active form of the molecule during ad-
ministration, commonly by the effect of enzymatic reactions
or other possible reactions inside the body [7]. The primary
goals of the prodrug approach can be outlined as follows:
targeted release, ameliorating absorption or membrane perme-
ability and decreasing metabolism or side effects [87]. The
generation of prodrugs from proteins/peptides appears to be
an attractive approach concerning the improvement and opti-
mization of their delivery because all the basic objectives of
this approach may be fulfilled with the modification of the
structure of biopharmaceuticals [88]. These hydrophilic mol-
ecules require a certain increase in lipophilicity to penetrate
the epithelial cell membrane and thus to cross the cells [89].
Chemical alteration on a reactive amino acid like lysine and
cysteine or other amino acids will not only give rise to
sustained absorption and reduce the amount of drug required
to produce the therapeutic effect but will also improve stability
as well as decrease immunogenicity [90, 91], and based on the
size of the conjugated molecule renal ultrafiltration may be
decreased due to the increased molecular size of the polypep-
tide [92]. The nature of the conjugated molecule may be var-
ied in a wide range such as direct modification by the use of
acetylation, C-amidation, N-pyroglutamate conjugation,
PEGylation (PEG) or glycosylation [93], or via the sugar part
of the glycoprotein [13]. Other strategies used for prodrug
formation include d-amino acid substitution, olefenic substi-
tution, carboxyl reduction, dehydro-amino acid substitution,
retro inversion modification and thiomethylene modification
[94]. Substantial success was achieved in producing protein
prodrugs, but due to the structural complexity of proteins, this
tool was unsatisfactory when attempting to modify most pro-
teins, and successful modification also faced the problem of
overall low yield [95].
Mimetic peptides approach
Parallel peptides are peptides with abnormal arrangement of
synthesized amino acids or incorporation of different new
linking bonds between those amino acids. The inclusion of
these chemical changes provides the preservation of peptides
against peptidases, which have high specificity towards nor-
mal peptides, but the main drawback of this approach is the
change or loss of the biological activity which should be
retained as the initial one [96].
Fatty acids-conjugation (lipidation) approach
Lipidation is the chemical alteration of a hydrophilic biomol-
ecule, made by the addition of a lipophilic entity mainly via
the acylation reaction to improve both the delivery and the
pharmacological efficiency of macromolecular drugs by
influencing membrane transport, metabolic stability and bio-
availability [97]. The covalent modification of proteins can be
done with various lipophilic substances, including
isoprenoids, lipid acids and fats. Accordingly, the lipidation
process has a great role in tailoring as well as in localizing
proteins [98]. Large numbers of proteins, including many pro-
teins utilized in the therapy of human diseases, are modified
by covalently linking fatty acids and/or isoprenoid groups,
which play a basic role in regulating their structure and func-
tion. Palmitate and myristate are the two fatty acids most com-
monly linked to proteins [99]. Reversible lipidation represents
an effective way to retain the basic biological activity of the
lipidized molecule. Lately, a reversible lipidation method has
been accomplished to guarantee the re-formation of the ther-
apeutic peptide from its lipidized form subsequent to oral ab-
sorption [89].
Cell penetration peptide (CPP) conjugation approach
CPP is a peptide with a high penetration capacity across the
absorptive cell membranes, thus a conjugation of the CPP to
macromolecular drugs like proteins will improve their kinet-
ics. Furthermore, a macromolecule and CPP can be adminis-
tered as a simple mixture [100]. At present, various non-
injection routes including nasal, pulmonary and oral routes
have been developed by utilizing a conjugate of CPP with
antidiabetic peptide for controlling blood glucose level.
Most of such research reported that after a suitable CPP con-
jugation with antidiabetic peptide hypoglycemic activity
could be retained. Furthermore, they show better stability
and resistance to proteolytic degradation [101].
Protein-polymer conjugation
In comparison with lipidation, the covalent conjugation of
proteins with various polymers offers the advantage of the
wider range of the targetable side chains, which results in
altered solubility, lipophilicity, targetability, crystallinity and
taste. Consequently, pharmaceutical and biotechnological
companies are conducting numerous studies and testing new
techniques to find the ideal modification [97]. Short chains of
both chitosan and polyethylene glycol (PEG) represent the
most utilized conjugates because they overcome the issue of
low solubility and improve the formulation stability in the GIT
[102]. Lee et al. developed a conjugate of insulin and low
molecular weight chitosan (LMWC) in an attempt to enhance
the oral delivery of insulin. The conjugates were found to have
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good ability to manage the plasma glucose level for several
hours in diabetic rat models, and they are considered as a
potential future technique for improving the efficacy of orally
administered therapeutic peptides and proteins [103].
Moreover, a conjugate of insulin and low relative molecular
mass protamine as CPP has been incorporated into
mucoadhesive nanoparticles (MNPs), and the composite
showed an effective delivery of insulin following oral appli-
cation. MNPs were found to render the loaded conjugates in
direct contact with the intestinal absorptive tissues. As a result
of their high permeation, it is possible for the released conju-
gates to be absorbed without digestion, and hence higher bio-
availability of insulin in diabetic rats has been obtained [104].
Lipid-based drug delivery system (LBDDS) approach
Lipid excipients are commonly involved in a formulation to
increase the absorption of drug molecules along the intestines
by different mechanisms, including limiting intestinally medi-
ated proteolysis, increasing membrane permeability and en-
hancing intestinal lymphatic uptake [105]. Therefore an
emerging interest was observed concerning LBDDSs over
the past two decades despite the pharmaceutical difficulties
entailed by these candidates [106]. Lipid-based carrier sys-
tems as drug vehicles are composed of physiological lipids
and offer several advantages, including high biocompatibility
and controlled release based on the nature of natural lipids, no
susceptibility to erosion phenomena compared to polymeric
systems, easy and simple manufacturing by compressing or
moulding, and slow water uptake after administration, which
may offer a less damaging environment for the loaded proteins
[107]. Thus, they have most of the advantages without the
risks and regulatory concerns involved in the direct conjuga-
tion of proteins with lipids.
Liposomal encapsulation approach
Liposomes are defined as microscopic vesicles with a spheri-
cal shape, consisting of two compartments, an inner aqueous
sinus surrounded by one or multiple homocentric lipid bilay-
ers. The liposomal membrane consists of reasonably biocom-
patible, biodegradable and non-immunogenic natural and/or
synthetic lipids usually stabilized with cholesterol, which also
extends the circulating time [108, 109]. The versatile nature of
liposomes enables lipophilic drugs to be incorporated within
the lipid bilayers, while lipophobic molecules like proteins
may be solubilized inside the internal aqueous core [110].
Therefore liposomal carriers were utilized for the successful
encapsulation of various therapeutic molecules like
tropicamide, artemether, paclitaxel, acyclovir, cyclosporine,
dithranol and chloroquine diphosphate [111]. In addition, they
represent excellent carriers for the delivery of protein antigens
as theymay be functionalized to mimic pathogens, which may
induce the immune system due to their enhanced uptake by
antigen presenting cells through various mechanisms, and the
increased exposure of liposome encapsulated antigens to the
lymphocytes of the immune system [112]. In recent years,
several liposome-based vaccines have been designed to deliv-
er oral antibodies to target several diseases caused by viruses
and bacteria, such as Salmonella enteritidis and influenza-A
viral vaccines. Thus, liposomes have shown high capacities to
deliver various antigens, such as peptides/proteins and DNA
[113].
Compared to various lipid carries, liposomes have high
capacity to enclose and protect labile molecules against the
hazardous GIT environment which would result in denatur-
ation, and they may also increase absorption into enterocytes
via the stimulation of their chylomicron production, thus pro-
moting drug transport [114]. Protein drugs of interest may be
both enclosed inside the liposomes or chemically attached to
the outer surface of the vesicles. The simple enclosure of a
macromolecule can be attained by the incubation of a macro-
molecular drug alongside the vesicles at or somewhat below
the transformation temperature of the constituting lipids,
whereas triggered (active) loading of biopharmaceuticals can
be achieved by the gentle swirling of liposomes in the pres-
ence of a buffered alcoholic solution of the proteins at elevated
temperature for a specified period of time [115].
Despite their numerous advantages, liposomes pose con-
siderable issues regarding physical, chemical and biological
stability, and these issues should be investigated and evaluated
thoroughly in the course of research, during and after prepa-
ration to achieve a good background stability profile.
Similarly, the development of general guidelines for the sta-
bility testing of liposomes would also be necessary [116]. The
chemical stability of lipids against hydrolysis or in the case of
unsaturated lipid chains also against oxidation is a point of
concern, especially during the storage period. Therefore, it is
recommended to store liposomes frozen or in a lyophilized
powder form, but in this case the re-check of their size distri-
bution, drug load and morphology before use is essential
[117]. Furthermore, the development of liposomal protein de-
livery systems has to face other challenges as well, such as low
protein loading efficiency, especially when using a small ves-
icle size (range of 50~150 nm), or the instability of the encap-
sulated protein during preparation, particularly under harsh
processing conditions or when using organic solvents [118].
Overall, numerous issues such as the presence of organic sol-
vent residues, physical and chemical instabilities, sterilization
and pyrogen control (when designed as injectable), variation
in size distribution, difficulties in batch to batch reproducibil-
ity and shortened half-life due to pancreatic lipase and bile
salts should be overcome during the formulation of liposomes.
This explains why only a limited number of liposome-based
drug formulations for oral delivery may be found on the mar-
ket today [119, 120]. A further issue is that liposomes
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designed to tolerate the harsh GI environment may exhibit
decreased permeability across GIT epithelia, which constitute
the main barrier to absorption [121]. However, the rational
design approach to attain therapeutic goals might represent
the rate-determining step in the development of more ad-
vanced liposome-based oral therapeutics in the future [122].
Solid lipid nanoparticles (SLNs)
To overcome the previously discussed drawbacks of lipo-
somes, two different research groups have developed SLNs
loaded with insulin for application via the oral route [123,
124]. SLNs are nanosized lipid carriers with particle sizes of
50–1000 nm, which remain solid at ambient and body tem-
peratures. SLNs usually contain physiological lipids, for ex-
ample, glyceride mixtures and steroids. They are stabilized by
biocompatible surfactants and represent an alternative to lipo-
somes and other nanoparticles [35, 125]. These loaded SLN
formulations exhibited good efficiency to improve the gastro-
intestinal absorption of insulin, which was confirmed by the
plasma sugar level of the tested rats, which was lower than that
of the rats receiving oral insulin solution and unloaded SLNs
(control) for one day. Accordingly, loaded SLNs showed a
partial protection of insulin against luminal proteases, there-
fore they are considered as stable carriers to deliver oral insu-
lin with good results of controlling plasma glucose level [123,
124].
SLNs are increasingly used as the protective delivery sys-
tems of labile drugs as well as to control/sustain the release of
incorporated molecules due to their low toxicity and superior
physical stability compared to other lipid-based carrier sys-
tems [126]. In addition, SLNs may have excellent reproduc-
ibility even with the use of various organic solvent-free
methods. Besides their relatively easy manufacturing, SLNs
may positively affect drug uptake through various ways, such
as enhancing the extent of solubility, hindering drug precipi-
tation upon dilution, suppressing efflux transporters, increas-
ing both membrane permeability and lymphatic uptake.
Nevertheless, despite the numerous advantages, the low load-
ing efficiency, particularly for hydrophilic drugs, and the pos-
sible expulsion of drugs after polymeric transition during stor-
age still pose considerable problems to scientists [127, 128].
In spite of these drawbacks, their flexibility in preparation and
the simplicity of large-scale production may encourage the
widespread use of SLNs [129].
Further enhancement of the orally administered medicinal
proteins may be accomplished if the lipid-based nanocarriers
are conjugated with polymers. In a recent study, poly lactic-
co-glycolic acid (PLGA)–lipid lipospheres were developed,
which consisted of a PLGA lipophilic interior and a self-
assembled lipophilic layer at the interface. These lipospheres
demonstrated high crossing efficiency along the microfold
cells (an in vivomodel), resulting in the efficient improvement
of the intestinal absorption for the loaded protein molecules
over regular polymeric nanoparticles [130]. Another research
group recently developed and formulated low molecular
weight (LMW) chitosan-lipid nanoparticle composites to de-
liver siRNA into the cytoplasm. The formulation gave prom-
ising results as it takes benefit of the mucoadhesive and
permeation-enhancing properties of chitosan as well as uti-
lizes the hydrophobic reservoir capacity of the hydrophobic
core of the hybrid particles [131].
Polymeric nanoparticles approach
From the pharmaceutical aspect, both polymeric micro- and
nanoparticles are of emerging interest since they show better
stability and therefore better preservation capacity against the
degrading effect of the GI environment compared to the car-
riers of fatty origin, such as liposomes [132]. The effective-
ness of protein drugs may be improved successfully with both
micro- and nanoencapsulation [133] via protection from hy-
drolysis and proteolytic enzymes and the improvement of
their absorption, in addition to their mucoadhesive properties
and permeation enhancing characteristics [134]. However, it
was observed that while microparticles are absorbed only
through the microfold cells, nanoparticles may also utilize
the same pathway and are also able to penetrate cell mem-
branes, therefore the quantity of nanosized carriers penetrating
through the intestinal membrane is higher compared to micro-
spheres [134]. The penetration and absorption enhancement
properties may be further improved by tailoring its surface
characteristics to adjust mucoadhesion property, lymphatic
and cellular uptake and site-specif ic absorption.
Nanoparticles are derived mainly from the most common
polymers, like poly (lactic-co-glycolic acid) PLGA, poly lac-
tic acid (PLA) and poly sebacic acid (PSA). These polymers
perform their mucoadhesivity through different possible
methods of interactions, such as covalent and non-covalent
bonding or the involvement of both [135]. From this aspect,
especially chitosan and its derivatives showed high safety,
biocompatibility, biodegradability and represent multifunc-
tional polymers since besides their extremely good
mucoadhesive properties, their penetration enhancing effect
was also reported [133]. Because of this multifunctionality,
chitosan NPs are promising drug delivery carriers suitable
for a wide group of drugs, including labile drugs and macro-
molecules [136, 137]. The combination of various polymers
and the utilization of oppositely charged polyelectrolytes like
chitosan, polyacrylic acid, alginate, polyalkylamine hydro-
chloride in the formulation of layer by layer (LBL) coated
nanoparticles may also offer further improvement and show
a great impact on both macromolecular drug stability and the
oral absorbability of protein from the GIT [138]. All in all,
mucoadhesive polymer nanoparticles were successfully used
for the delivery of the extracellular products (ECPs) of Vibrio
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anguillarum to deliver oral vaccination in turbots [139], where
it was confirmed that the process of insulin uptake seemed to
be a joint process of both insulin crossing the intestinal cells
and the uptake of the insulin loaded nanoparticles by aggre-
gated lymphoid nodules. However, Yao et al. showed themain
limitations of nanoparticulate carrier systems are usually as-
sociated with limited loading efficiency and particle agglom-
eration due to thermodynamic instability [140], which was
also observed by Gao et al., who found that the efficiency of
loading was only 57.8 ± 2.54% for the turbot vaccination
[139].
Self-assembling bubbles carrier approach
Besides the previously discussed approaches, recent studies
by the research group of Chuang E-Y introduced a very inno-
vative bubble carrier system as delivery vehicle for the oral
delivery of insulin, with possible application as a technique for
the oral application of other medicinal macromolecules [141].
This self-assembling bubble carrier composed of pentetic ac-
id, carbonate, surface active agent and insulin was enclosed in
oral capsules and enterically coated to bypass gastric acidity.
Once the formulation reaches the lower part of GIT fluids, it
breaks down and releases acid and bicarbonate, which react
quickly and produce carbon dioxide, which acts as a transport-
er for the involved insulin. The obvious elevation in plasma
insulin level accompanied with a decrease in plasma glucose
level was noticed in diabetic rats. Accordingly, self-
assembling bubble carriers represent an effective and safe
method suitable to deliver other biologically activemacromol-
ecules [55].
Conclusion
The oral delivery of biopharmaceuticals is a challenging re-
search area as a result of many difficulties, for example, the
rigid physical barriers of absorptive tissues for these high mo-
lecular mass, hydrophilic drugs, and the degradation by gas-
tric juice and intestinal metabolizing enzymes, all together
acting as pharmacokinetic barriers and are responsible for
the absorption of a tiny amount of the orally administered
dose. Accordingly, the first step in the formulation requires
comprehensive knowledge about these barriers. For this rea-
son, most attempts focused on overcoming the enzymatic bar-
rier within the lumen and on improving the permeation of
macromolecules.
This review reveals the versatility of methods and involved
excipients to overcome the bioavailability problem. From in-
dustrial aspect, the combination of mucoadhesive polymers,
EIs and PEs in a conventional dosage form appears to be the
most applicable approach, as the concurrent release of these
excipients may form appropriate microenvironment to obviate
the protease barrier and achieve facilitated absorption of the
loaded macromolecules. Especially if the effect is localized on
the absorption site by the mucoadhesivity of the carrier which
increases the chance for absorption. However, the incorpora-
tion of these agents may be critical and hence careful screen-
ing is required. Nevertheless, some molecules such as phenyl
piperazine (0.1%w/w), SDS, chitosan and its derivatives were
investigated recently and regarded as potential enhancers with
reliable safety. The use of multifunctional excipients such as
CA to inhibit enzymatic activity by the careful modification of
the pH in which peptidases are more active at the targeted
absorption site as well as to facilitate paracellular absorption
by modulating the permeability of TJs due to the chelating of
membrane-bound calcium may further increase the safety of
the carrier.
PEGylation by attaching one or more PEG series was de-
veloped to increase the circulating time and hide the linked
macromolecule from the enzymatic attack, but PEGylation
and other prodrug models may conflict with the general reg-
ulatory rules and may require more intensive testing of the
produced conjugate.
The utilization of lipid-based nanocarriers (e.g. liposomes
or SLNs) for the delivery of macromolecules seems to be an
efficient technique for oral administration as it provides pro-
tection and internalization through the stimulation of intestinal
lipoprotein transporters and the possibility to encapsulate hy-
drophilic and hydrophobic molecules at the same time. On the
other hand, the difficulty to reproduce in the same manner,
physical and chemical instability during storage, low loading
capacity and degradation by pancreatic lipase represent the
main limitations and may restrict their utilization as oral mac-
romolecule carriers. From the aspect of reproducibility, SLNs
are better than liposomes. However, due to the lack of the
hydrophilic interior, they provide poor drug loading capacity
for hydrophilic macromolecules and hence, the expulsion of
hydrophilic drugs was observed during storage, which consid-
erably decreases the shelf-life of these products.
From the aspect of stability and loading capacity,
mucoadhesive polymeric micro/nanocarriers may offer better
solution compared to lipid nanocarriers, due to their more
hydrophilic structure. However, despite their protecting effect
against both luminal and mucosal secretions and enzymes
their effectiveness in enhancement of therapeutic effect may
be limited due to their lower internalization efficiency.
Nevertheless, among them, chitosan micro/nanoparticles
proved to be prospective drug delivery carriers as they offer
many advantages, including safety, biocompatibility, biode-
gradability, micro/nanosized nature and the ability to open
reversibly TJs, which may facilitate drug uptake through the
cell membrane, while their mucoadhesive property increases
the residence time at the site of absorption.
Accordingly, it can be concluded that formulation of
hybridlipid/polymeric micro/nanoparticles would be the most
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appropriate carrier systems for the oral delivery of therapeutic
macromolecules as it may provide appropriate loading capac-
ity and stability with improved internalization capacity.
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